期刊
PROSTATE CANCER AND PROSTATIC DISEASES
卷 12, 期 3, 页码 296-300出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/pcan.2009.18
关键词
PTGS2; polymorphism; case-control; epidemiology
资金
- UK NIHR Health Technology Assessment Programme [96/20/06, 96/20/99]
- National Cancer Research Institute (NCRI) formed by the Department of Health
- Medical Research Council and Cancer Research UK
- World Cancer Research Fund
- MRC [G0500966, G0600705] Funding Source: UKRI
- Medical Research Council [G0600705, G0500966] Funding Source: researchfish
Prostaglandin endoperoxidase synthase 2 is a key regulator of inflammation and may play a role in prostate carcinogenesis. The polymorphism, -899G>C (rs20417), alters a transcription factor-binding site and is associated with a reduced risk of colorectal adenoma. We tested the hypothesis that rs20417 may influence prostate cancer risk, using a large case-control study (n(cases) = 1608, n(controls) = 3058). We found no evidence that rs20417 alters prostate cancer risk (odds ratio (ORCC & GC v GG = 1.05, 95% confidence interval (CI) 0.91-1.20). A meta-analysis of three studies also found little evidence that rs20417 alters risk (pooled ORCC (& GC v GG) 1.04, 95% CI 0.93-1.17), making it unlikely that rs20417 contributes in any major way to prostate cancer aetiology. Prostate Cancer and Prostatic Diseases (2009) 12, 296-300; doi: 10.1038/pcan.2009.18; published online 2 June 2009
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据